Familial pulmonary arterial hypertension by KDR heterozygous loss of function

Beyond the major gene BMPR2, several new genes predisposing to PAH have been identified during the last decade. Recently, preliminary evidence of the involvement of the KDR gene was found in a large genetic association study. We prospectively analysed the KDR gene by targeted panel sequencing in a series of 311 PAH patients referred to a clinical molecular laboratory for genetic diagnosis of PAH. Two index cases with severe PAH from two different families were found to carry a loss-of-function mutation in the KDR gene. These two index cases were clinically characterised by low diffusing capacity for carbon monoxide adjusted for haemoglobin (DLCOc) and interstitial lung disease. In one family, segregation analysis revealed that variant carriers are either presenting with PAH associated with low DLCOc, or have only decreased DLCOc, whereas non-carrier relatives have normal DLCOc. In the second family, a single affected carrier was alive. His carrier mother was unaffected with normal DLCOc. We provided genetic evidence for considering KDR as a newly identified PAH-causing gene by describing the segregation of KDR mutations with PAH in two families. In our study, KDR mutations are associated with a particular form of PAH characterised by low DLCOc and radiological evidence of parenchymal lung disease including interstitial lung disease and emphysema. KDR mutations were identified in two families with a particular form of PAH characterised by low DLCOc and radiological evidence of parenchymal lung disease http://bit.ly/30npPPn

[1]  Yufeng Shen,et al.  Reduced transfer coefficient of carbon monoxide in pulmonary arterial hypertension implicates rare protein-truncating variants in KDR , 2019 .

[2]  W. Seeger,et al.  Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension. , 2019, American journal of respiratory and critical care medicine.

[3]  W. Chung,et al.  Genetics and genomics of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[4]  M. Humbert,et al.  Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives , 2019, European Respiratory Journal.

[5]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[6]  Y. Mao,et al.  Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension , 2019, European Respiratory Journal.

[7]  M. Humbert,et al.  Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases , 2019, European Respiratory Journal.

[8]  Sunday S. Oladipupo,et al.  Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1) , 2018, Scientific Reports.

[9]  Henning Gall,et al.  Identification of rare sequence variation underlying heritable pulmonary arterial hypertension , 2018, Nature Communications.

[10]  M. Eyries,et al.  Genetic analyses in a cohort of children with pulmonary hypertension , 2016, European Respiratory Journal.

[11]  N. Westerhof,et al.  Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[12]  D. Penny,et al.  Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report , 2016, BMC Pulmonary Medicine.

[13]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[14]  M. Humbert,et al.  Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects , 2015, Human mutation.

[15]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[16]  A. Alzoubi,et al.  Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats. , 2014, American journal of physiology. Heart and circulatory physiology.

[17]  W. Chung,et al.  A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[18]  E. Bongers,et al.  TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension , 2013, Journal of Medical Genetics.

[19]  W. Chung,et al.  Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension , 2012, Circulation. Cardiovascular genetics.

[20]  Jing Zheng,et al.  Deciphering mechanisms controlling placental artery endothelial cell migration stimulated by vascular endothelial growth factor. , 2010, Endocrinology.

[21]  L. Farkas,et al.  VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. , 2009, The Journal of clinical investigation.

[22]  Manuel Corpas,et al.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. , 2009, American journal of human genetics.

[23]  S. Surrey,et al.  Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis , 2008, Journal of cellular and molecular medicine.

[24]  G. Perkins,et al.  Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells , 2007, Critical care medicine.

[25]  N. Voelkel,et al.  Vascular endothelial growth factor in the lung. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[26]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[27]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[28]  M. Shibuya,et al.  A single autophosphorylation site on KDR/Flk‐1 is essential for VEGF‐A‐dependent activation of PLC‐γ and DNA synthesis in vascular endothelial cells , 2001, The EMBO journal.

[29]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  M. Humbert,et al.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[31]  P. Hirth,et al.  Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. , 2000, The Journal of clinical investigation.

[32]  H. Farber,et al.  VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[33]  N. Voelkel,et al.  Inhibition of angiogenesis decreases alveolarization in the developing rat lung. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[34]  J. Shannon,et al.  Tissue interactions mediate early events in pulmonary vasculogenesis , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[35]  A Shinkai,et al.  Mapping of the Sites Involved in Ligand Association and Dissociation at the Extracellular Domain of the Kinase Insert Domain-containing Receptor for Vascular Endothelial Growth Factor* , 1998, The Journal of Biological Chemistry.

[36]  W. Teague,et al.  Reduced gas transfer at rest and during exercise in school-age survivors of bronchopulmonary dysplasia. , 1998, American journal of respiratory and critical care medicine.

[37]  Janet Rossant,et al.  A Requirement for Flk1 in Primitive and Definitive Hematopoiesis and Vasculogenesis , 1997, Cell.

[38]  K. Alitalo,et al.  The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells , 1993, The Journal of experimental medicine.

[39]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.